KU ASH 2019 Review: Current Updates in Hematologic Diseases

 

Myeloid Session
13:23

KU ASH 2019 Review: Current Updates in Hematologic Diseases

ASH 2019 Update on MDS: Definitions and the Notion of Risk

FEATURING Mikkael Sekeres
  • 13 views
  • February 13, 2020
14:52

KU ASH 2019 Review: Current Updates in Hematologic Diseases

ASH 2019 Update on Low-Risk MDS: Ameliorating Anemia

FEATURING Mikkael Sekeres
  • 16 views
  • February 13, 2020
05:28

KU ASH 2019 Review: Current Updates in Hematologic Diseases

ASH 2019 Update on Low-Risk MDS: Tackling Thrombocytopenia / Modifying Multilineage Dysplasia

FEATURING Mikkael Sekeres
  • 16 views
  • February 13, 2020
09:05

KU ASH 2019 Review: Current Updates in Hematologic Diseases

ASH 2019 Update on the Higher-Risk MDS: HMA & HCT - Need to Focus on Response Duration and Overall Survival, Goals of Therapy Should Reflect Goals of Patient

FEATURING Mikkael Sekeres
  • 53 views
  • February 13, 2020
06:19

KU ASH 2019 Review: Current Updates in Hematologic Diseases

ASH 2019 Update: Adding Targeted Agents to Intensive Therapy in AML Looks Promising

FEATURING Heather Male
  • 22 views
  • February 13, 2020
09:18

KU ASH 2019 Review: Current Updates in Hematologic Diseases

ASH 2019 Update: Understanding the Leukemia Mutational Profile in a Timely Fashion Helps "Unfit" & R/R AML Patients

FEATURING Heather Male
  • 114 views
  • February 13, 2020
  • 1
10:05

KU ASH 2019 Review: Current Updates in Hematologic Diseases

ASH 2019 Update: CC-486 Demonstrated Improvement in OS and RFS in Maintenance Therapy for AML

FEATURING Heather Male
  • 106 views
  • February 13, 2020
36:19

KU ASH 2019 Review: Current Updates in Hematologic Diseases

ASH 2019 Update on Myeloproliferative Neoplasms: CPI-0610 (BET Inhibitor) Mono or + Ruxolitinib Demonstrated Antitumor Activity in R/R/I Disease

FEATURING Ronald Hoffman
  • 21 views
  • February 13, 2020
20:32

KU ASH 2019 Review: Current Updates in Hematologic Diseases

ASH 2019 Update on the Bone Marrow Procedures with a Dry Tap: KUH Dry Tap Protocol - Emerging Data May Point Towards Using MRD in Treatment Strategies

FEATURING Janet Woodroof
  • 6 views
  • February 13, 2020
30:09

KU ASH 2019 Review: Current Updates in Hematologic Diseases

KU ASH 2019 Review: There Is a Potential Role for Allogeneic HCT After Venetoclax-Based Induction in AML Elderly Patients

FEATURING Haitham Abdelhakim
  • 17 views
  • February 24, 2020
27:18

KU ASH 2019 Review: Current Updates in Hematologic Diseases

KU ASH 2019 Review: Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of the Axicabtagene Ciloleucel and Tisagenlecleucel for R/R DLBCL

FEATURING Joseph McGuirk
  • 168 views
  • February 24, 2020
  • 1
11:50

KU ASH 2019 Review: Current Updates in Hematologic Diseases

KU ASH 2019 Review: CAR T-Cell Therapy is Highly Effective for R/R Mantle Cell Lymphoma, BCMA Is a Promising Target in R/R Multiple Myeloma

FEATURING Joseph McGuirk
  • 60 views
  • February 24, 2020
13:05

KU ASH 2019 Review: Current Updates in Hematologic Diseases

KU ASH 2019 Review on Benign Hematology: Sutimlimab in CAD, Erythroferrone Regulates Fe Homeostasis in Beta Thalassemia, B2GP in APS ELANE Gene Editing in SCN

FEATURING Penelope Harris
  • 33 views
  • February 24, 2020
17:49

KU ASH 2019 Review: Current Updates in Hematologic Diseases

KU ASH 2019 Review on Benign Hematology: New FDA Approvals, 2nd-Line cITP After Steroids Gene Therapy for Hemophilia B, ASH Guidelines

FEATURING Penelope Harris
  • 104 views
  • February 24, 2020